Please ensure Javascript is enabled for purposes of website accessibility

3 Horrendous Health-Care Stocks This Week

By Keith Speights - Feb 22, 2014 at 8:38AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Which health-care stocks experienced the agony of defeat this week?

It's always fun watching the best of the best compete in the Winter Olympic games. But, of course, not everyone can win. Plenty of athletes experience the proverbial agony of defeat.

That's the case with investing, too. Not every stock can be a winner. Several health-care stocks proved the point this week. One of the worst performers announced disappointing clinical study results. Two others were slammed in online articles by short-sellers. 

Which health-care stocks emerged as the most horrendous of all? Find out by watching the following slideshow.

 

Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
GWPH
Onconova Therapeutics, Inc. Stock Quote
Onconova Therapeutics, Inc.
ONTX
$1.23 (-2.38%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.